Drug Profile
Florbetapir F 18 - Avid Radiopharmaceuticals
Alternative Names: 18F-AV-45; Amyloid imaging agent; Amyvid; AV-45; Florbetapir (18F); Florpiramine F 18Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator University of Pennsylvania
- Developer Avid Radiopharmaceuticals; Chang Gung Memorial Hospital
- Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alzheimer's disease
- Phase II Cognition disorders
- No development reported Parkinson's disease
Most Recent Events
- 29 Nov 2022 Phase II development in Cognition disorders (Diagnosis, In adults, In the elderly) is ongoing in Taiwan (IV) (NCT04588649)
- 16 May 2022 Avid Pharmaceuticals terminated a phase II trial in Alzhiemers disease in Netherlands (EudraCT2012-001599-12)
- 27 Aug 2021 Invicro initiates a phase I trial to compare amyloid burden assessed by amyloid PET imaging in USA (NCT05164536)